MYC and rectal cancer: In rectal cancer, O-GlcNAc modification of c-Myc at Ser415 enhances the stability of c-Myc and increases the expression of pyruvate dehydrogenase kinase 2 (PDK2), which reduces mitochondrial pyruvate metabolism, inhibits ROS production, and promotes the growth of xenograft tumors (166).